A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue

Results in Pharma Sciences

Volumn 1, Issue 1, 2011, Pages 49-56

  Gjetting, Torben ^a,b   Andresen, Thomas Lars ^b   Christensen, Camilla Laulund ^a   Cramer, Frederik ^a   Poulsen, Thomas Tuxen ^a   Poulsen, Hans Skovgaard ^a  

^a FINSEN LABORATORY   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Biodistribution; Gene delivery; Liposome; Stabilized plasmid lipid particle (SPLP); Suicide gene therapy; Xenograft tumor model

Indexed keywords

1,2 DISTEAROYLGLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYLGLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; BETA ACTIN; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DISTEAROYLPHOSPHATIDYLCHOLINE; NUCLEIC ACID; PLASMID DNA; REAGENT; STABILIZED PLASMID LIPID PARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER TISSUE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG HALF LIFE; ENCAPSULATION; GENE ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; PERMEABILITY; PRIORITY JOURNAL; REPORTER GENE; SUICIDE GENE THERAPY; TUMOR XENOGRAFT;

EID: 80052682252     PISSN: None     EISSN: 22112863     Source Type: Journal    
DOI: 10.1016/j.rinphs.2011.08.001     Document Type: Article

References (37)

1. Kang HC, Lee M, Bae YH. Polymeric gene carriers. Critical Reviews in Eukaryotic Gene Expression 2005;15:317-42.
2. Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods in Molecular Biology 2008;433:159-75.
3. Ahmad A, Evans HM, Ewert K, George CX, Samuel CE, Safinya CR. New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid-DNA complexes for gene delivery. Journal of Gene Medicine 2005;7:739-48.
4. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposo-mal Doxorubicin: review of animal and human studies. Clinical Pharmacokinetics 2003;42:419-36.
5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research 1994;54:98 7-92.
6. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation 2001;41:189-207.
7. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, Maclachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharmaceutical Research 2005;22:362-72.
8. Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophysical Journal 2001;80:2310-26.
9. Skjorringe T, Gjetting T, Jensen TG. A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs). Journal of Controlled Release 2009;139:140-5.
10. Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, Maclachlan I. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Molecular Therapy 2007;15:713-20.
11. Tam P, Monck M, Lee D, Ludkovski O, Leng EC, Clow K, et al. Stabilized plasmid-lipid particles for systemic gene therapy. Gene Therapy 2000;7:1867-74.
12. Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS. Specifically targeted gene therapy for small-cell lung cancer. Expert Review of Anticancer Therapy 2009;9:437-52.
13. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clinical Cancer Research 2010;16:2308-19.
14. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treatment Reviews 2004;30:521-43.
15. Rivest V, Phivilay A, Julien C, Belanger S, Tremblay C, Emond V, et al. Novel liposomal formulation for targeted gene delivery. Pharmaceutical Research 2007;24:981-90.
16. Wheeler JJ, Palmer L, Ossanlou M, Maclachlan I, Graham RW, Zhang YP, et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Therapy 1999;6:271-81.
17. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochimica et Biophysica Acta 2001;1515:167-76.
18. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochimica et Biophysica Acta 2004;1663:167-77.
19. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta-Biomembranes 2001;1510:152-66.
20. Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. Journal of Gene Medicine 2003;5:1039-45.
21. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, et al. In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterolmediated gene transfection. International Journal of Nano-medicine 2010;5:371-83.
22. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Science USA 1991;88:11460-4.
23. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Advanced Drug Delivery Reviews 2010.
24. Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, Maclachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochimica et Biophysica Acta 2005;1669:155-63.
25. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology 2010;28:172-6.
26. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Molecular Therapy 2006;13:328-37.
27. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, Maclachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnology 2005;23:45 7-62.
28. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 2002;20:709-60.
29. Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. International Journal of Hyperthermia 2008;24:475-82.
30. Ogawara K, Un K, Tanaka K, Higaki K, Kimura T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. Journal of Controlled Release 2009;133:4-10.
31. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta 1991; 1066:29-36.
32. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochimica et Biophysica Acta 1990;1029:91-7.
33. Gabizon A, Pappo O, Goren D, Chemla M, Tzemach D, Horowitz A. Preclinical studies with doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Journal of Liposome Research 1993;3:517-28.
34. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today 2006;11:812-8.
35. Heyes J, Hall K, Tailor V, Lenz R, Maclachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. Journal of Controlled Release 2006;112:280-90.
36. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. Cytosolic drug delivery using pH- and light-sensitive liposomes. Advanced Drug Delivery Reviews 1999;38:317-38.
37. Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. International Journal of Pharmaceutics 2008;354:39-48.